382 related articles for article (PubMed ID: 28637922)
1. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.
Yaspan BL; Williams DF; Holz FG; Regillo CD; Li Z; Dressen A; van Lookeren Campagne M; Le KN; Graham RR; Beres T; Bhangale TR; Honigberg LA; Smith A; Henry EC; Ho C; Strauss EC;
Sci Transl Med; 2017 Jun; 9(395):. PubMed ID: 28637922
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.
Holz FG; Sadda SR; Busbee B; Chew EY; Mitchell P; Tufail A; Brittain C; Ferrara D; Gray S; Honigberg L; Martin J; Tong B; Ehrlich JS; Bressler NM;
JAMA Ophthalmol; 2018 Jun; 136(6):666-677. PubMed ID: 29801123
[TBL] [Abstract][Full Text] [Related]
3. Complement inhibitors for age-related macular degeneration.
Tzoumas N; Riding G; Williams MA; Steel DH
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD009300. PubMed ID: 37314061
[TBL] [Abstract][Full Text] [Related]
4. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS; Lad EM; Holz FG; Rosenfeld PJ; Guymer RH; Boyer D; Grossi F; Baumal CR; Korobelnik JF; Slakter JS; Waheed NK; Metlapally R; Pearce I; Steinle N; Francone AA; Hu A; Lally DR; Deschatelets P; Francois C; Bliss C; Staurenghi G; Monés J; Singh RP; Ribeiro R; Wykoff CC;
Lancet; 2023 Oct; 402(10411):1434-1448. PubMed ID: 37865470
[TBL] [Abstract][Full Text] [Related]
5. Complement inhibition as a therapeutic strategy in retinal disorders.
Kassa E; Ciulla TA; Hussain RM; Dugel PU
Expert Opin Biol Ther; 2019 Apr; 19(4):335-342. PubMed ID: 30686077
[TBL] [Abstract][Full Text] [Related]
6. Emixustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy.
Jack LS; Sadiq MA; Do DV; Nguyen QD
Dev Ophthalmol; 2016; 55():302-9. PubMed ID: 26501510
[TBL] [Abstract][Full Text] [Related]
7. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ; Westby K; Csaky KG; Monés J; Pearlman JA; Patel SS; Joondeph BC; Randolph J; Masonson H; Rezaei KA
Ophthalmology; 2021 Apr; 128(4):576-586. PubMed ID: 32882310
[TBL] [Abstract][Full Text] [Related]
8. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Liao DS; Grossi FV; El Mehdi D; Gerber MR; Brown DM; Heier JS; Wykoff CC; Singerman LJ; Abraham P; Grassmann F; Nuernberg P; Weber BHF; Deschatelets P; Kim RY; Chung CY; Ribeiro RM; Hamdani M; Rosenfeld PJ; Boyer DS; Slakter JS; Francois CG
Ophthalmology; 2020 Feb; 127(2):186-195. PubMed ID: 31474439
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules.
Nebbioso M; Lambiase A; Cerini A; Limoli PG; La Cava M; Greco A
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987401
[TBL] [Abstract][Full Text] [Related]
10. Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration.
Freeman WR; Bandello F; Souied E; Guymer RH; Garg SJ; Chen FK; Rich R; Holz FG; Patel SS; Kim K; López FJ;
Ophthalmol Retina; 2023 Jul; 7(7):573-585. PubMed ID: 36906177
[TBL] [Abstract][Full Text] [Related]
11. A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy.
Le KN; Gibiansky L; Good J; Davancaze T; van Lookeren Campagne M; Loyet KM; Morimoto A; Jin J; Damico-Beyer LA; Hanley WD
J Pharmacol Exp Ther; 2015 Nov; 355(2):288-96. PubMed ID: 26359312
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches.
Loyet KM; Hass PE; Sandoval WN; Morando A; Liu P; Shatz W; Dickmann L; Kenrick M; Good J; Davancaze T; Morimoto AM; Kelley RF; Scheer JM
Mol Pharm; 2019 Jan; 16(1):86-95. PubMed ID: 30444371
[TBL] [Abstract][Full Text] [Related]
13. Maximum Reading Speed in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Varma R; Souied EH; Tufail A; Tschosik E; Ferrara D; Zhang J; Silverman D; Dolan C; Bressler NM
Invest Ophthalmol Vis Sci; 2018 Mar; 59(4):AMD195-AMD201. PubMed ID: 30383205
[TBL] [Abstract][Full Text] [Related]
14. Age-related macular degeneration: a complementopathy?
Kijlstra A; Berendschot TT
Ophthalmic Res; 2015; 54(2):64-73. PubMed ID: 26159686
[TBL] [Abstract][Full Text] [Related]
15. Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials.
Heier JS; Pieramici D; Chakravarthy U; Patel SS; Gupta S; Lotery A; Lad EM; Silverman D; Henry EC; Anderesi M; Tschosik EA; Gray S; Ferrara D; Guymer R;
Ophthalmol Retina; 2020 Jul; 4(7):673-688. PubMed ID: 32199866
[TBL] [Abstract][Full Text] [Related]
16. Complement cascade inhibition in geographic atrophy: a review.
Desai D; Dugel PU
Eye (Lond); 2022 Feb; 36(2):294-302. PubMed ID: 34999723
[TBL] [Abstract][Full Text] [Related]
17. Investigational drugs inhibiting complement for the treatment of geographic atrophy.
Ferro Desideri L; Artemiev D; Bernardi E; Paschon K; Zandi S; Zinkernagel M; Anguita R
Expert Opin Investig Drugs; 2023; 32(11):1009-1016. PubMed ID: 37902056
[TBL] [Abstract][Full Text] [Related]
18. Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical Trial.
Rosenfeld PJ; Dugel PU; Holz FG; Heier JS; Pearlman JA; Novack RL; Csaky KG; Koester JM; Gregory JK; Kubota R
Ophthalmology; 2018 Oct; 125(10):1556-1567. PubMed ID: 29716784
[TBL] [Abstract][Full Text] [Related]
19. PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Kuppermann BD; Patel SS; Boyer DS; Augustin AJ; Freeman WR; Kerr KJ; Guo Q; Schneider S; López FJ;
Retina; 2021 Jan; 41(1):144-155. PubMed ID: 32134802
[TBL] [Abstract][Full Text] [Related]
20. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.
Patel SS; Lally DR; Hsu J; Wykoff CC; Eichenbaum D; Heier JS; Jaffe GJ; Westby K; Desai D; Zhu L; Khanani AM
Eye (Lond); 2023 Dec; 37(17):3551-3557. PubMed ID: 36964259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
